$69.00
CJC-1295 is a synthetic analog of growth hormone–releasing hormone (GHRH) engineered for increased stability and prolonged activity. It is commonly referenced in endocrinology and peptide research focused on pituitary signaling and growth hormone regulatory pathways. Supplied strictly for laboratory research use only.
For research purposes only. Not for human consumption
CJC-1295 was developed to enhance the half-life of native GHRH by incorporating structural modifications that reduce enzymatic degradation [1]. In molecular and preclinical research, CJC-1295 is used to study GHRH receptor activation, cyclic AMP signaling, and downstream regulation of growth hormone release at the pituitary level [2]. Variants of CJC-1295, including DAC (Drug Affinity Complex) forms, have been examined for their ability to bind serum albumin, allowing sustained receptor engagement in experimental models [3]. These characteristics make CJC-1295 a useful reference compound in peptide pharmacokinetics and endocrine signaling research.
In laboratory and animal research models, CJC-1295 is primarily studied in endocrinology, metabolism, and aging-related research frameworks. Published literature explores its role in pulsatile growth hormone signaling, insulin-like growth factor (IGF-1) axis studies, and neuroendocrine regulation under controlled experimental conditions [4]. Additional investigations focus on structure–activity relationships of GHRH analogs and their impact on receptor selectivity and signaling duration [5][6]. These studies position CJC-1295 as a valuable tool for researchers examining growth hormone biology, peptide modification strategies, and long-acting hormone analog design. This compound is not intended for human or veterinary use.
